TY - JOUR
T1 - Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification
T2 - The ishinomaki COPD network registry
AU - Kobayashi, Seiichi
AU - Hanagama, Masakazu
AU - Ishida, Masatsugu
AU - Sato, Hikari
AU - Ono, Manabu
AU - Yamanda, Shinsuke
AU - Yamada, Mitsuhiro
AU - Aizawa, Hiroyuki
AU - Yanai, Masaru
N1 - Publisher Copyright:
© 2018 Kobayashi et al.
PY - 2018
Y1 - 2018
N2 - Purpose: The GOLD report provides a framework for classifying COPD in a way that reflects its clinical impact and allows treatment recommendations. The GOLD 2017 proposes a new classification whereby patients are grouped as A–D according to their symptoms and history of exacerbations. However, the clinical characteristics and outcomes in these patients are not well documented. Patients and methods: In this prospective observational study, we analyzed data from the Ishinomaki COPD Network Registry. All patients with stable COPD were classified into the four groups defined by GOLD 2017. The patient demographics, clinical characteristics, number of exacerbations, and mortality rate during 1 year of follow-up were compared between the groups. Results: Four hundred and one patients with stable COPD were identified. There were 240 patients (59.9%) in group A, 122 (30.4%) in group B, 16 (4.0%) in group C, and 23 (5.7%) in group D. Patients in groups B, C, and D had ORs of 2.95, 3.92, and 5.45, respectively, for risk of exacerbation relative to group A. Groups C and D experienced exacerbations more frequently, including exacerbations leading to hospital admission, than groups A and B (both P<0.001) during the 1-year follow-up period. Patients with a high risk of exacerbation (groups C and D) had a lower body mass index, showed more symptoms, used more respiratory medications, and had more severe airflow limitation than patients at low risk of exacerbation (groups A and B). Mortality was not different between the high-risk and low-risk groups. Conclusion: The results of our study provide evidence that the GOLD 2017 classification identifies patients with COPD at risk of exacerbations, including those requiring hospitalization, but has a poor ability to predict mortality.
AB - Purpose: The GOLD report provides a framework for classifying COPD in a way that reflects its clinical impact and allows treatment recommendations. The GOLD 2017 proposes a new classification whereby patients are grouped as A–D according to their symptoms and history of exacerbations. However, the clinical characteristics and outcomes in these patients are not well documented. Patients and methods: In this prospective observational study, we analyzed data from the Ishinomaki COPD Network Registry. All patients with stable COPD were classified into the four groups defined by GOLD 2017. The patient demographics, clinical characteristics, number of exacerbations, and mortality rate during 1 year of follow-up were compared between the groups. Results: Four hundred and one patients with stable COPD were identified. There were 240 patients (59.9%) in group A, 122 (30.4%) in group B, 16 (4.0%) in group C, and 23 (5.7%) in group D. Patients in groups B, C, and D had ORs of 2.95, 3.92, and 5.45, respectively, for risk of exacerbation relative to group A. Groups C and D experienced exacerbations more frequently, including exacerbations leading to hospital admission, than groups A and B (both P<0.001) during the 1-year follow-up period. Patients with a high risk of exacerbation (groups C and D) had a lower body mass index, showed more symptoms, used more respiratory medications, and had more severe airflow limitation than patients at low risk of exacerbation (groups A and B). Mortality was not different between the high-risk and low-risk groups. Conclusion: The results of our study provide evidence that the GOLD 2017 classification identifies patients with COPD at risk of exacerbations, including those requiring hospitalization, but has a poor ability to predict mortality.
KW - Chronic obstructive pulmonary disease
KW - Exacerbations
KW - GOLD
KW - GOLD 2017
KW - Mortality
UR - http://www.scopus.com/inward/record.url?scp=85058491143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058491143&partnerID=8YFLogxK
U2 - 10.2147/COPD.S182905
DO - 10.2147/COPD.S182905
M3 - Article
C2 - 30584294
AN - SCOPUS:85058491143
SN - 1176-9106
VL - 13
SP - 3947
EP - 3955
JO - International Journal of COPD
JF - International Journal of COPD
ER -